ストックスクリーナーアプリを入手
7.06
4.75%
0.32
アフターアワーズ：
7.06
前日終値:
$6.74
開ける：
$6.85
24時間の取引高:
2.49M
Relative Volume:
0.96
時価総額：
$718.36M
収益：
-
当期純損益:
$-29.07M
株価収益率:
-24.34
EPS:
-0.29
ネットキャッシュフロー:
$-31.85M
1週間 パフォーマンス:
+8.45%
1か月 パフォーマンス:
+7.29%
6か月 パフォーマンス:
+155.80%
1年 パフォーマンス:
+185.83%
1日の値動き範囲:
$6.76
$7.095
1週間の範囲:
$5.3801
$7.48
52週間の値動き範囲:
$2.30
$7.48
Trevi Therapeutics Inc Stock (TRVI) Company Profile
名前
Trevi Therapeutics Inc
セクター
電話
203-304-2499
住所
195 CHURCH STREET, NEW HAVEN, CT
TRVI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.06 | 647.10M | 0 | -29.07M | -31.85M | -0.29 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 繰り返されました | Needham | Buy |
| 2025-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-30 | 開始されました | Raymond James | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-12 | 開始されました | B. Riley Securities | Buy |
| 2022-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | BMO Capital Markets | Outperform |
| 2019-06-03 | 開始されました | Needham | Buy |
| 2019-06-03 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | Stifel | Buy |
すべてを表示
Trevi Therapeutics Inc (TRVI) 最新ニュース
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Trevi Therapeutics Closes Public Offering - marketscreener.com
Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - PR Newswire
Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq
Trevi Therapeutics Announces Public Offering Pricing - TipRanks
Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress
Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com
H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada
Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - Insider Monkey
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey
Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada
Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa
Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa
Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India
Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks
Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK
Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com
Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus
Trevi Therapeutics launches $100 million stock offering - Investing.com
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus
Clinical-Stage Biotech Trevi Therapeutics Seeks $100M in Major Stock Offering with Morgan Stanley Leading - Stock Titan
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga
trevi therapeutics reports positive results from phase 2b cough trial - Investing.com Australia
trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Nigeria
Transcript : Trevi Therapeutics, Inc.Special Call - marketscreener.com
Trevi Therapeutics Reports Positive Phase 2b Trial Results - TipRanks
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Ca - GuruFocus
Trevi Therapeutics Announces Positive Topline Results From Phase 2B Coral Trial Of Haduvio - marketscreener.com
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Achieves Positive Results in Cough Treatment Trial | TRVI Stock News - GuruFocus
Clinical Trial Success: Trevi's Haduvio Achieves 60% Cough Reduction in IPF PatientsFirst Potential Treatment - Stock Titan
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - The Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - The Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2 - GuruFocus
Critical Phase 2b Results Coming: Trevi's Novel IPF Chronic Cough Drug Could Change Treatment Landscape - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts - Defense World
What is HC Wainwright’s Forecast for TRVI Q2 Earnings? - Defense World
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating - MSN
Trevi Therapeutics to Participate in Upcoming June Conferences | - GuruFocus
Trevi Therapeutics to Participate in Upcoming June Conferences - Citizen Tribune
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at HC Wainwright - Defense World
Trevi Therapeutics Inc (TRVI) 財務データ
収益
当期純利益
現金流量
EPS
Trevi Therapeutics Inc (TRVI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
0.00%
2.33%
大文字化:
|
ボリューム (24 時間):